Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Mitoxantrone Combination Regimen in Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
NCT06761417Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2025
- Primary completion
- Apr 2027
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone-liposome in solid tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate up to 18 weeks. Started Jan 2025; status: recruiting.
02
Drugs
mitoxantrone-liposome
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06761417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06761417.